ArriVent BioPharma, Inc. Common Stock (AVBP)vsModerna Inc (MRNA)
AVBP
ArriVent BioPharma, Inc. Common Stock
$15.95
+1.40%
HEALTHCARE · Cap: $884.58M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
AVBP leads profitability with a 0.0% profit margin vs -141.4%. AVBP earns a higher WallStSmart Score of 26/100 (F).
AVBP
Avoid26
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVBP.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity, Altman Z-Score, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AVBP profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
AVBP carries more volatility with a beta of 1.35 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
AVBP generates stronger free cash flow (-40M), providing more financial flexibility.
Bottom Line
AVBP scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune diseases. The company harnesses proprietary technologies and a strong scientific foundation to create a promising pipeline aimed at enhancing patient outcomes. Positioned in high-growth sectors of the biopharma industry, ArriVent presents an appealing investment opportunity for institutional investors looking to engage in impactful healthcare innovations with substantial market potential.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?